The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies
Open accessAbstract
The development of a drug-resistant cell line can take from 3 to 18 months. However, little is published on the methodology of this development process. This article will discuss key decisions to be made prior to starting resistant cell line development; the choice of parent cell line, dose of selecting agent, treatment interval, and optimizing the dose of drug for the parent cell line. Clinically relevant drug-resistant cell lines are developed by mimicking the conditions cancer patients experience during chemotherapy and cell lines display between two- and eight-fold resistance compared to their parental cell line. Doses of drug administered are low, and a pulsed treatment strategy is often used where the cells recover in drug-free media. High-level laboratory models are developed with the aim of understanding potential mechanisms of resistance to chemotherapy agents. Doses of drug are higher and escalated over time. It is common to have difficulty developing stable clinically relevant drug-resistant cell lines. A comparative selection strategy of multiple cell lines or multiple chemotherapeutic agents mitigates this risk and gives insight into which agents or type of cell line develops resistance easily. Successful selection strategies from our research are presented. Pulsed-selection produced platinum or taxane-resistant large cell lung cancer (H1299 and H460) and temozolomide-resistant melanoma (Malme-3M and HT144) cell lines. Continuous selection produced a lapatinib-resistant breast cancer cell line (HCC1954). Techniques for maintaining drug-resistant cell lines are outlined including; maintaining cells with chemotherapy, pulse treating with chemotherapy, or returning to master drug-resistant stocks. The heterogeneity of drug-resistant models produced from the same parent cell line with the same chemotherapy agent is explored with reference to P-glycoprotein. Heterogeneity in drug-resistant cell lines reflects the heterogeneity that can occur in clinical drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clonogenic assay of cells in vitro
Franken, N. A. P., Rodermond, H. M., Stap, J., Haveman, J., & van Bree, C. (2006) · Nature Protocols · doi:10.1038/nprot.2006.339 · Cited by 4,188
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Self-citationCarboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
Tumor heterogeneity: Causes and consequences
Marusyk, A., & Polyak, K. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.11.002 · Cited by 1,602
Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M., Aamdal, S., Cebon, J., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,272
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Biedler, J. L., & Riehm, H. (1970) · PubMed · Cited by 747
Temozolomide and treatment of malignant glioma
Friedman, H. S., Kerby, T., & Calvert, H. (2000) · PubMed · doi:10.25405/ncl.34644405 · Cited by 731
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
Burris, H. A., Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K. L., O'Neil, B., Marcom, P. K., Ellis, M. J., Overmoyer, B., Jones, S. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.584 · Cited by 619
Hamilton, T. C., Young, R. C., McKoy, W. M., Grotzinger, K. R., Green, J. A., Chu, E. W., Whang‐Peng, J., Rogan, A. M., Green, W. R., & Ozols, R. F. (1983) · PubMed · Cited by 539
Isolation and genetic characterization of human KB cell lines resistant to multiple drugs
Akiyama, S.-I., Fojo, A., Hanover, J. A., Pastan, I., & Gottesman, M. M. (1985) · Somatic Cell and Molecular Genetics · doi:10.1007/bf01534700 · Cited by 529
Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL
Liu, L., Greger, J., Shi, H., Liu, Y., Greshock, J., Annan, R., Halsey, W., Sathe, G. M., Martin, A.-M., & Gilmer, T. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4490 · Cited by 495
Goldenberg, M. M. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88288-0 · Cited by 453
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
Gerlinger, M., & Swanton, C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605912 · Cited by 421
Xia, W., Bacus, S., Hegde, P., Husain, I., Strum, J., Liu, L., Paulazzo, G., Lyass, L., Trusk, P., Hill, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602468103 · Cited by 374
Gazdar, A. F., Kurvari, V., Virmani, A., Gollahon, L., Sakaguchi, M., Westerfield, M., Kodagoda, D., Stasny, V., Cunningham, H. T., Wistuba, I. I., et al. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19981209)78:6<766::aid-ijc15>3.0.co;2-l · Cited by 341
Comparative properties of five human ovarian adenocarcinoma cell lines.
Buick, R. N., Pullano, R., & Trent, J. M. (1985) · PubMed · Cited by 326
O'Brien, N. A., Browne, B. C., Chow, L., Wang, Y., Ginther, C., Arboleda, J., Duffy, M. J., Crown, J., O'Donovan, N., & Slamon, D. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1171 · Cited by 324
Self-citationSakai, W., Swisher, E. M., Jacquemont, C., Chandramohan, K. V., Couch, F. J., Langdon, S. P., Wurz, K., Higgins, J., Villegas, E., & Taniguchi, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1178 · Cited by 321
Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice.
Bénard, J., Silva, J. D., Blois, M. C. D., Boyer, P. J. J., Duvillard, P., Chiric, E., & RIOU, G. F. (1985) · PubMed · Cited by 287
Phase I trial of temozolomide using an extended continuous oral schedule.
Brock, C., Newlands, E. S., Wedge, S. R., Bower, M., Evans, H. S., Colquhoun, I. R., Roddie, M., Glaser, M. G., Brampton, M., & Rustin, G. J. S. (1998) · PubMed · Cited by 284
Wang, Y.-C., Morrison, G., Gillihan, R., Guo, J., Ward, R. M., Fu, X., Botero, M. F., Healy, N. A., Hilsenbeck, S. G., Phillips, G. L., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3067 · Cited by 280
Barr, M. P., Gray, S. G., Hoffmann, A. C., Hilger, R. A., Thomale, J., O’Flaherty, J. D., Fennell, D. A., Richard, D., O’Leary, J. J., & O’Byrne, K. J. (2020) · PLOS ONE · doi:10.1371/journal.pone.0233739 · Cited by 269
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Langdon, S. P., Lawrie, S. S., Hay, F. G., Hawkes, M. M., McDonald, A. W., Hayward, I. P., Schol, D. J., Hilgers, J., Leonard, R. C., & Smyth, J. F. (1988) · PubMed · Cited by 269
Metallothionein gene expression and resistance to cisplatin in human ovarian cancer
Schilder, R. J., Hall, L., Monks, A., Handel, L. M., Fornace, A. J., Ozols, R. F., Fojo, A. T., & Hamilton, T. C. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910450306 · Cited by 185
Hills, C., Kelland, L., Abel, G., Siracky, J., Wilson, A., & Harrap, K. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.108 · Cited by 183
Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma
Cooke, S. L., Ng, C. K. Y., Melnyk, N., Garcia, M. J., Hardcastle, T., Temple, J., Langdon, S., Huntsman, D., & Brenton, J. D. (2010) · Oncogene · doi:10.1038/onc.2010.245 · Cited by 178
Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response.
Kessel, D. H., Botterill, V., & Wodinsky, I. (1968) · PubMed · Cited by 176
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib
Huang, C., Park, C. C., Hilsenbeck, S. G., Ward, R., Rimawi, M. F., Wang, Y.-C., Shou, J., Bissell, M. J., Osborne, C. K., & Schiff, R. (2011) · Breast Cancer Research · doi:10.1186/bcr2936 · Cited by 165
Varma, M. V. S., Sateesh, K., & Panchagnula, R. (2005) · Molecular Pharmaceutics · doi:10.1021/mp0499196 · Cited by 161
Evolutionary Pathways in BRCA1-Associated Breast Tumors
Martins, F. C., De, S., Almendro, V., Gönen, M., Park, S. Y., Blum, J. L., Herlihy, W. G., Ethington, G., Schnitt, S. J., Tung, N., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0325 · Cited by 154
Temozolomide for the Treatment of Metastatic Melanoma: A Systematic Review
Quirt, I. C., Verma, S., Petrella, T. M., et al. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1114 · Cited by 143
Rexer, B. N., Ham, A.-J. L., Rinehart, C., Hill, S., de Matos Granja-Ingram, N., González-Angulo, A. M., Mills, G. B., Dave, B., Chang, J. C., Liebler, D. C., et al. (2011) · Oncogene · doi:10.1038/onc.2011.130 · Cited by 139
DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance
Stronach, E. A., Chen, M. M., Maginn, E. N., Agarwal, R., Mills, G. B., Wasan, H. S., & Gabra, H. (2011) · Neoplasia · doi:10.1593/neo.111032 · Cited by 138
Martin, A., & CLYNES, M. M. (1993) · Cytotechnology · doi:10.1007/bf00749057 · Cited by 135
Self-citationHamaguchi, K., Godwin, A. K., YAKUSHIJI, M., O'Dwyer, P. J., Ozols, R. F., & Hamilton, T. C. (1993) · PubMed · Cited by 133
Pohl, G., Ho, C., Kurman, R. J., Bristow, R. E., Wang, T., & Shih, I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3625 · Cited by 123
Joerger, M., Huitema, A. D. R., van den Bongard, H. J. G. D., Schellens, J. H. M., & Beijnen, J. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2069 · Cited by 120
Acid phosphatase: Endpoint for in vitro toxicity tests
Martin, A. J., & CLYNES, M. M. (1991) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/bf02630912 · Cited by 103
Self-citationLiang, X., Shen, D., Garfield, S. H., & Gottesman, M. M. (2003) · PubMed · Cited by 95
Stordal, B., Hamon, M., McEneaney, V., Roche, S., Gillet, J., O’Leary, J. J., Gottesman, M. M., & CLYNES, M. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040717 · Cited by 89
Self-citationPerego, P., Romanelli, S., Carenini, N., Magnani, I., Leone, R., Bonetti, A. V., Paolicchi, A., & Zunino, F. (1998) · Annals of Oncology · doi:10.1023/a:1008265012435 · Cited by 86
Shen, D.-W., Akiyama, S.-I., Schoenlein, P. V., Pastan, I. H., & Gottesman, M. M. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.134 · Cited by 82
Aird, K. M., Ghanayem, R. B., Peplinski, S., Lyerly, H. K., & Devi, G. R. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0160 · Cited by 75
Yamamoto, N., Nokihara, H., Yamada, Y., Goto, Y., Tanioka, M., Shibata, T., Yamada, K., Asahina, H., Kawata, T., Shi, X., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02179.x · Cited by 73
Davey, R., Longhurst, T., Davey, M. W., Belov, L., Harvie, R. M., Hancox, D., & Wheeler, H. (1995) · Leukemia Research · doi:10.1016/0145-2126(94)00159-8 · Cited by 68
Martin, A. P., Miller, A. V., Emad, L., Rahmani, M., Walker, T. D., Mitchell, C., Hagan, M. P., Park, M. A., Yacoub, A., Fisher, P. B., et al. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.047365 · Cited by 67
Xia, W., Bacus, S. S., Husain, I., Liu, L.-H., Zhao, S., Liu, Z., Moseley, M. A., Thompson, J. W., Chen, F. L., Koch, K. M., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1041 · Cited by 55
Tegze, B., Szállási, Z., Haltrich, I., Pénzváltó, Z., Tóth, Z., Likó, I., & Győrffy, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030804 · Cited by 52
The pharmacokinetics of a 1-h paclitaxel infusion
Mross, K. B., Holl�nder, N., Hauns, B., Schumacher, M., & Maier-Lenz, H. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051020 · Cited by 52
Cullen, K. V., Davey, R. A., & Davey, M. W. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00681-5 · Cited by 48
Kim, H. K., Lin, C., Parker, D., Veals, J., Lim, J. M., Likhari, P., Statkevich, P., Marco, A., & Nomeir, A. A. (1997) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(97)00431-3 · Cited by 47
Stability of c-K-ras amplification during progression in a patient with adenocarcinoma of the ovary.
Filmus, J., & Buick, R. N. (1985) · PubMed · Cited by 47
Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells
Stordal, B., Davey, M. W., & Davey, R. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0148-7 · Cited by 36
Self-citationLapatinib: A dual tyrosine kinase inhibitor for metastatic breast cancer
Paul, B., Trovato, J. A., & Thompson, J. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070646 · Cited by 36
Ma, J., Maliepaard, M., Kolker, H. J., Verweij, J., & Schellens, J. H. M. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050727 · Cited by 34
A cell line from a human ovarian carcinoma with amplification of the K-ras gene.
Filmus, J., Trent, J. M., Pullano, R., & Buick, R. N. (1986) · PubMed · Cited by 34
Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines
Xu, H., Choi, S.-M., Choi, S.-M., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.015 · Cited by 32
Mackillop, W. J., Trent, J. M., Stewart, S. S., & Buick, R. N. (1983) · PubMed · Cited by 31
Azzabi, A., Hughes, A. N., Calvert, P., Plummer, E. R., Todd, R., Griffin, M. J., Lind, M., Maraveyas, A., Kelly, C. M., Fishwick, K., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602438 · Cited by 24
Modulation of drug and radiation resistance in small cell lung cancer cells by paclitaxel
Locke, V. L., Davey, R., & Davey, M. W. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200308000-00004 · Cited by 16
Stordal, B., Peters, G. B., & Davey, R. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20373 · Cited by 16
Self-citationEmoto, M., Oshima, K., Ishiguro, M., et al. (1999) · Pathology - Research and Practice · doi:10.1016/s0344-0338(99)80040-5 · Cited by 11
Cited by
Yang, C., Li, Z., Bhatt, T., Dickler, M., Giri, D., Scaltriti, M., Baselga, J., Rosen, N., & Chandarlapaty, S. (2017) · Oncogene · doi:10.1038/onc.2016.379 · Cited by 415
Toward a Better Understanding of the Complexity of Cancer Drug Resistance
Gottesman, M. M., Lavi, O., Hall, M. D., & Gillet, J.-P. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103111 · Cited by 327
Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer
Enriquez-Navas, P. M., Kam, Y., Das, T., Hassan, S., Silva, A., Foroutan, P., Ruiz, E., Martinez, G., Minton, S., Gillies, R. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7842 · Cited by 322
Luebker, S. A., & Koepsell, S. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00268 · Cited by 194
A microfluidic platform for drug screening in a 3D cancer microenvironment
Pandya, H. J., Dhingra, K., Prabhakar, D., Chandrasekar, V., Natarajan, S. K., Vasan, A. S., Kulkarni, A., & Shafiee, H. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.03.054 · Cited by 76
Metadata
- Authors
- McDermott, M., Eustace, A. J., Busschots, S., Breen, L., Crown, J., Clynes, M., O’Donovan, N., & Stordal, B.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2014-03-06
- Volume
- 4
- Pages
- 40-40
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2098791934
- Cited by
- 315
- References
- 64
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.